An Open-Label Extension Study for Patients with Dravet Syndrome who Previously Participated in Studies of STK-001

What is the goal of the study?

This study is a Phase 2/3, multi-center, open-label, multiple dose, safety extension study for patients who have completed the End of Study visit in Study STK-001-DS-101 and satisfy criteria for continued treatment in this Open Label Extension (OLE) study. The primary purpose of this study is to gather additional information on the long-term safety, tolerability, and impact on seizure frequency and duration of repeated doses of STK-001 administered every 4 months by intrathecal (IT) injection. We expect 1-3 participants to be enrolled.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

• PI (Study Doctor): Russell Saneto
• Study Team Member: Laurie Guidry, [email protected]